At PEAR, we are focused on the development of prescription digital therapeutics to treat diseases with high unmet medical need.

Breaking News

April 18, 2018

Pear Therapeutics and Sandoz Announce Deal to Commercialize Prescription Digital Therapeutics

PEAR IS A FULLY INTEGRATED, PRESCRIPTION DIGITAL THERAPEUTICS COMPANY

We are developing software-based, prescription digital therapeutics designed to treat severe medical conditions. PEAR is seeking FDA clearance for these products. Our development process examines the clinical impact of these interventions in randomized clinical trials. We strive to provide enhanced outcomes for patients, supportive engagement and tracking tools for clinicians, and cost-effective solutions for payers.

PRESCRIPTION DIGITAL THERAPEUTICS TO TREAT UNMET NEED

PEAR has developed a pipeline of clinically validated, prescription digital therapeutics.

The first FDA-cleared prescription digital therapeutic for the treatment of patients with substance use disorder (SUD)

The first prescription digital therapeutic designed to treat opioid use disorder (OUD) in conjunction with opioid replacement therapy

The first prescription digital therapeutic designed to treat schizophrenia

The first prescription digital therapeutic using virtual reality exposure therapy to treat post traumatic stress disorder (PTSD)

Pear PipelinePEAR is also working on Generalized Anxiety Disorder (GAD), post-surgical pain, Major Depressive Disorder (MDD), and insomnia, among other indications.

PEAR’s lead products, reSET® and reSET-OTM have been evaluated in 6 randomized clinical trials involving over 1500 patients.*

Pear reSET®
reSET

In a clinical trial involving patients diagnosed with Substance Use Disorder (SUD), reSET® nearly doubled the rate of abstinence and increased retention in treatment compared to standard face-to-face therapy.*

Pear reSET®

reSET

Clinical trials have been completed to support the use of reSET-OTM in the treatment of Opiate Use Disorder (OUD) when used in conjunction with opioid replacement therapies.

THRIVETM has been examined in three clinical studies involving 1,279 patients. Efficacy has been demonstrated as assessed by PANSS (the aggregate approvable endpoint for schizophrenia therapies) and patient engagement has been demonstrated beyond six months.

* Therapeutic Education System (TES), which has equivalent content to reSET®, was tested. Please see labeling for study details.